High flow nasal cannula in acute hypercapnic exacerbation of chronic obstructive pulmonary disease: an emerging utility

Submitted: August 24, 2019
Accepted: December 15, 2019
Published: January 21, 2020
Abstract Views: 1946
PDF: 1290
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


High flow nasal cannula (HFNC) provides warmed and humidified air with flow rates up to 60 liters/min with relatively fixed oxygen content (FiO2). It has been extensively evaluated for hypoxemic respiratory failure and has been used in mild acute respiratory distress syndrome, pre-intubation, bronchoscopy and pediatric obstructive sleep apnea. Recent data has suggested a role in stable hypercapnic chronic obstructive pulmonary disease (COPD) and even in acute exacerbations, though, the use has not been advocated by any guidelines yet. We present a case of acute hypercapnic exacerbation of COPD, intolerant to non-invasive ventilation, showing response and improvement on use of HFNC. This case highlights this potential mechanisms and prospects for the same.



PlumX Metrics


Download data is not yet available.


How to Cite

Mittal, Anshul, Megha Varshney, Vidushi Rathi, and Pranav Ish. 2020. “High Flow Nasal Cannula in Acute Hypercapnic Exacerbation of Chronic Obstructive Pulmonary Disease: An Emerging Utility”. Monaldi Archives for Chest Disease 90 (1). https://doi.org/10.4081/monaldi.2020.1158.